A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
33 patients were enrolled and 27 were evaluable.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Future studies should evaluate combination therapies with pembrolizumab. [TRIALS REGISTRATION] Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP); ClinicalTrials.gov Identifier: NCT03391973; https://clinicaltrials.gov/study/NCT03391973?cond=CUP&term=Monzon&rank= 1.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] Carcinoma of unknown primary (CUP) is a heterogeneous group of cancers with no identifiable primary lesion, but metastatic epithelial disease.
- 95% CI 2.35-29.16
APA
Monzon JG, Karachiwala H, et al. (2026). A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.. European journal of cancer (Oxford, England : 1990), 239, 116709. https://doi.org/10.1016/j.ejca.2026.116709
MLA
Monzon JG, et al.. "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.." European journal of cancer (Oxford, England : 1990), vol. 239, 2026, pp. 116709.
PMID
41935492 ↗
Abstract 한글 요약
[BACKGROUND] Carcinoma of unknown primary (CUP) is a heterogeneous group of cancers with no identifiable primary lesion, but metastatic epithelial disease. The diagnosis portends a poor prognosis with limited systemic therapy options. Researchers hypothesize that these primary lesions are occult, in part, due to anti-cancer immune surveillance.
[METHODS] This was a non-randomized, multi-center phase 2 trial of pembrolizumab administered at 200 mg intravenously every 3-weeks in patients with untreated CUP. The primary endpoint was measuring safety and objective response rate (ORR). Secondary objectives included progression free survival (PFS) and overall survival (OS).
[RESULTS] In total 33 patients were enrolled and 27 were evaluable. The median age was 64 (range 21-80), the majority were male (57.6%) and ECOG 1 (84.8%). There were no new signals of toxicity. The ORR was 11.1% (95% CI 2.35-29.16%) and disease control rate was 51.9% as per RECIST criteria. The median PFS and OS were 2.98 (95% CI 2.07-4.63) and 9.49 (95% CI 3.84-14.72) months respectively. The one patient who developed a complete response had mismatch repair (MMR) deficiency and has completed 2 years of therapy. Of the 2 patients with a partial response, one had an MMR proficient tumour, while the remaining 1 had unknown MMR status. Higher PD-L1 score was associated with response to pembrolizumab.
[CONCLUSIONS] This is the first study investigating the safety and efficacy of pembrolizumab in untreated CUP patients. Some responses were observed, but this primary endpoint was not met. We recommend screening all CUP patients for MMR/microsatellite instability (MSI). Future studies should evaluate combination therapies with pembrolizumab.
[TRIALS REGISTRATION] Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP); ClinicalTrials.gov Identifier: NCT03391973; https://clinicaltrials.gov/study/NCT03391973?cond=CUP&term=Monzon&rank= 1.
[METHODS] This was a non-randomized, multi-center phase 2 trial of pembrolizumab administered at 200 mg intravenously every 3-weeks in patients with untreated CUP. The primary endpoint was measuring safety and objective response rate (ORR). Secondary objectives included progression free survival (PFS) and overall survival (OS).
[RESULTS] In total 33 patients were enrolled and 27 were evaluable. The median age was 64 (range 21-80), the majority were male (57.6%) and ECOG 1 (84.8%). There were no new signals of toxicity. The ORR was 11.1% (95% CI 2.35-29.16%) and disease control rate was 51.9% as per RECIST criteria. The median PFS and OS were 2.98 (95% CI 2.07-4.63) and 9.49 (95% CI 3.84-14.72) months respectively. The one patient who developed a complete response had mismatch repair (MMR) deficiency and has completed 2 years of therapy. Of the 2 patients with a partial response, one had an MMR proficient tumour, while the remaining 1 had unknown MMR status. Higher PD-L1 score was associated with response to pembrolizumab.
[CONCLUSIONS] This is the first study investigating the safety and efficacy of pembrolizumab in untreated CUP patients. Some responses were observed, but this primary endpoint was not met. We recommend screening all CUP patients for MMR/microsatellite instability (MSI). Future studies should evaluate combination therapies with pembrolizumab.
[TRIALS REGISTRATION] Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP); ClinicalTrials.gov Identifier: NCT03391973; https://clinicaltrials.gov/study/NCT03391973?cond=CUP&term=Monzon&rank= 1.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.